GLP-1 Drugs Cut Breast Cancer Risk 30% and Curb Spread by Up to 50%
Updated
Updated · The Guardian · Jun 2
GLP-1 Drugs Cut Breast Cancer Risk 30% and Curb Spread by Up to 50%
3 articles · Updated · The Guardian · Jun 2
Three studies presented at ASCO in Chicago linked GLP-1 weight-loss drugs to lower cancer risk and better outcomes, including a 30% drop in breast cancer incidence and a 30% lower death risk in treated patients.
A 110,000-woman observational analysis found GLP-1 users were 30% less likely to develop breast cancer, while a separate study of 27,000 patients tied the drugs plus standard care to lower mortality.
A third study of 12,000 patients found people with breast, lung, bowel or liver cancer who took the drugs were 38% to 50% less likely to progress to stage-four disease.
Researchers said the effect may reflect both weight loss and the drugs' anti-inflammatory, metabolic and immune-modulating actions, but outside experts stressed the evidence is still observational and needs prospective trials.
The findings add to growing interest in repurposing GLP-1 medicines—first used for diabetes and now widely used for obesity—as potential tools for cancer prevention, treatment support and side-effect management.
Beyond weight loss, do these popular drugs possess a secret, direct power to halt tumor growth?
If a weight-loss drug becomes our best cancer shield, who will be able to afford this protection?
As millions use these drugs, what unknown health risks could emerge years from now?
25% Reduction in Breast Cancer Risk with GLP-1 Medications: Evidence, Safety, and Next Steps
Overview
Emerging research highlights that GLP-1 receptor agonists (GLP-1 RAs) may significantly reduce the risk and progression of breast cancer. This effect is linked to their strong ability to help with weight loss, which is important because being overweight or obese increases breast cancer risk, especially for post-menopausal women. GLP-1 RAs not only support weight management but also reduce systemic inflammation and may have other metabolic and epigenetic effects that could help prevent tumor growth. These combined actions suggest that GLP-1 RAs could play a valuable role in breast cancer prevention and care.